Bioorganic & Medicinal Chemistry Letters 2010-12-15

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

Yun W Alelyunas, James R Empfield, Dennis McCarthy, Russell C Spreen, Khanh Bui, Luciana Pelosi-Kilby, Cindy Shen

Index: Bioorg. Med. Chem. Lett. 20 , 7312-6, (2010)

Full Text: HTML

Abstract

We determined the experimental solubility of CNS marketed drugs. Of the 98 drugs measured, greater than 90% had solubility >10 μM in pH 7.4 buffer. Only seven drugs had solubility <10 μM. Using these data, we established a solubility criterion to support CNS discovery. The implication of poor solubility with potential safety concerns and undesirable side effects are discussed.Copyright © 2010 Elsevier Ltd. All rights reserved.

Related Compounds

Structure Name/CAS No. Articles
Sulpiride Structure Sulpiride
CAS:15676-16-1
Carbamazepine Structure Carbamazepine
CAS:298-46-4
Lidocaine Structure Lidocaine
CAS:137-58-6
Valproic acid Structure Valproic acid
CAS:99-66-1
Gabapentin Structure Gabapentin
CAS:60142-96-3
(-)-δ9-trans-Tetrahydrocannabinol Structure (-)-δ9-trans-Tetrahydrocannabinol
CAS:1972-08-3
diazepam Structure diazepam
CAS:439-14-5
Alprazolam Structure Alprazolam
CAS:28981-97-7
Vigabatrin Structure Vigabatrin
CAS:68506-86-5
Ibuprofen Structure Ibuprofen
CAS:15687-27-1